Trial Profile

A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; MOMA 341 (Primary)
Indications Colorectal cancer; Endometrial cancer; Gastric cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors MOMA Therapeutics

Most Recent Events

23 May 2025 Status changed from planning to not yet recruiting.
07 Apr 2025 New trial record
01 Apr 2025 According to MOMA Therapeutics media release, company anticipates to enter clinic with MOMA-341 in Q2 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com